Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

Mycobacterium leprae

(Immuno-prophylactic: all children in endemic areas. Immuno-therapeutic: all recently infected individuals)

Armadillo-derived M. leprae

88,481

271

Neisseria meningitidis

(Infants, 3–6 months)

Conjugated capsular polysaccharides, groups A,C,Y, and W135

13,754

708

Parainfluenza viruses

(Infants)

Trivalent, subunit vaccine (which must contain fusion proteins)

43,692

1,697

Plasmodium spp.

(All infants at risk, military personnel, travelers)

Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation

475,205

967

Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)

426,640

857

Rabies virus

(Individuals at high risk, plus post-exposure prophylaxis) (As above)

Vero cell

41,910

147

Glycoprotein produced by rDNA technology in mammalian cells

37,983

139

(Birth cohort in areas of high risk)

Attenuated live vector virus containing gene for protective glycoprotein antigen

8,260

16

Respiratory syncytial virus

(Infants)

Polypeptides produced by recombinant DNA technology

52,412

1,964

Attenuated live virus

59,559

983



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement